Citadel Advisors
ZYNE

Citadel Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Citadel Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,500
Closed -$8.31K – 15451
2023
Q2 		$8.31K Buy
25,500
+12,300
+93% +$4.41K ﹤0.01% 13326
2023
Q1 		$5.68K Sell
13,200
-7,700
-37% -$4.06K ﹤0.01% 13855
2022
Q4 		$11.1K Sell
20,900
-16,200
-44% -$10.3K ﹤0.01% 13590
2022
Q3 		$27K Buy
37,100
+3,100
+9% +$3.52K ﹤0.01% 11962
2022
Q2 		$39K Buy
34,000
+10,000
+42% +$12.7K ﹤0.01% 12083
2022
Q1 		$49K Sell
24,000
-39,100
-62% -$93K ﹤0.01% 12805
2021
Q4 		$182K Sell
63,100
-34,200
-35% -$127K ﹤0.01% 11992
2021
Q3 		$413K Sell
97,300
-15,300
-14% -$68.3K ﹤0.01% 10335
2021
Q2 		$596K Sell
112,600
-16,700
-13% -$80.3K ﹤0.01% 9642
2021
Q1 		$601K Buy
129,300
+37,000
+40% +$168K ﹤0.01% 9289
2020
Q4 		$305K Buy
92,300
+15,700
+20% +$59.6K ﹤0.01% 9050
2020
Q3 		$254K Sell
76,600
-209,800
-73% -$771K ﹤0.01% 8417
2020
Q2 		$965K Buy
286,400
+242,100
+547% +$1.14M ﹤0.01% 5899
2020
Q1 		$170K Sell
44,300
-51,900
-54% -$241K ﹤0.01% 8173
2019
Q4 		$581K Sell
96,200
-12,400
-11% -$84.8K ﹤0.01% 6586
2019
Q3 		$821K Buy
108,600
+42,700
+65% +$481K ﹤0.01% 5932
2019
Q2 		$893K Sell
65,900
-8,800
-12% -$102K ﹤0.01% 5874
2019
Q1 		$405K Buy
74,700
+10,900
+17% +$53K ﹤0.01% 7143
2018
Q4 		$189K Buy
63,800
+3,600
+6% +$19.7K ﹤0.01% 7906
2018
Q3 		$491K Buy
60,200
+26,800
+80% +$206K ﹤0.01% 6735
2018
Q2 		$325K Sell
33,400
-300
-0.9% -$3.08K ﹤0.01% 7079
2018
Q1 		$293K Sell
33,700
-19,600
-37% -$211K ﹤0.01% 6786
2017
Q4 		$667K Sell
53,300
-79,000
-60% -$905K ﹤0.01% 5234
2017
Q3 		$1.11M Buy
132,300
+61,200
+86% +$647K ﹤0.01% 4174
2017
Q2 		$1.21M Buy
71,100
+47,400
+200% +$942K ﹤0.01% 3822
2017
Q1 		$476K Buy
23,700
+12,500
+112% +$248K ﹤0.01% 5115
2016
Q4 		$175K Buy
+11,200
New +$151K ﹤0.01% 6396

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's ZYNE Position: Q1 2023 in Review

Citadel Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 17,471 shares — an estimated $9.21K sold.

Citadel Advisors first reported a position in ZYNE in Q3 2016 and held it in 16 quarters. The position peaked at $7.78M in Q2 2017. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Citadel Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 17,471 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $9.21K.
  • Citadel Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 16 quarters.
  • Citadel Advisors's Zynerba Pharmaceuticals, Inc position peaked at $7.78M in Q2 2017.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.